Modern approaches to the treatment of Cushing’s disease

Andreeva A.V.

Endocrinological dispansery Health Care Department, Moscow, Russia;
City Clinical Hospital named after V.V. Veresaev, Moscow, Russia

Markina N.V.

Éndokrinologicheskiĭ dispanser Departamenta zdravookhraneniia Moskvy

Antsiferov M.B.

Éndokrinologicheskiĭ dispanser Departamenta zdravookhraneniia Moskvy

Modern approaches to the treatment of Cushing’s disease

Authors:

Andreeva A.V., Markina N.V., Antsiferov M.B.

More about the authors

Journal: Problems of Endocrinology. 2016;62(4): 50‑55

DOI: 10.14341/probl201662450-55

Downloaded: 15

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Andreeva AV, Markina NV, Antsiferov MB. Modern approaches to the treatment of Cushing’s disease. Problems of Endocrinology. 2016;62(4):50‑55. (In Russ.)
https://doi.org/10.14341/probl201662450-55

Close metadata

Traditionally the Cushing’s disease (CD) is considered a rare disease. Since 2012 СD has the official status of an orphan disease in the Russian Federation. Now prevalence of this disease in the world are from 1,5 to 3,9 cases of CD on 1 million people of the population. The reason of CD is the adenoma of a hypophysis (сortiсotropinoma). The "gold" standard of therapeutic tactics of patients with CD is the transsphenoidal surgery. However in 20% of cases after the radical treatment fail to achieve remission of pathological process. Now in an arsenal of the neuroendocrinologist we have various methods of therapy, including various methods of drug therapy. The focus of preparations are central type action: analogs of a somatostatin. The representative of this group of preparations is Pasireotid who has proved the efficiency by results of the multicenter clinical trials. This review focuses of the current state of knowledge about methods of treatment of CD, about new therapeutic opportunities with application of analogs of a somatostatin.

Keywords:

hypercortisolism

Cushing’s disease

ACTH-depended hypercortisolism

treatment of Cushing’s disease

analog of somatostatin

pasireotid

Authors:

Andreeva A.V.

Endocrinological dispansery Health Care Department, Moscow, Russia;
City Clinical Hospital named after V.V. Veresaev, Moscow, Russia

Markina N.V.

Éndokrinologicheskiĭ dispanser Departamenta zdravookhraneniia Moskvy

Antsiferov M.B.

Éndokrinologicheskiĭ dispanser Departamenta zdravookhraneniia Moskvy

List of references:

Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994;40(4):479-484.
Дедов И.И., Мельниченко Г.А. Болезнь Иценко-Кушинга. / Методические Рекомендации. - М.: Министерство Здравоохранения Российской Федерации; 2012. [Dedov II, Melnichenko GF. Cushing Disease. Clinical Guidelines. Moscow: Ministry Of Health Of Russian Federation. 2012]. (In Russ.).
Белая Ж.Е. Ранняя диагностика эндогенного гиперкортицизма. Канонический WNT сигнальный путь и изменение костного метаболизма при глюкокортикоидном остеопорозе: Дисс. … д-ра мед. наук. - М. 2014. [Belaya ZE. Rannyaya Diagnostika Endogennogo Giperkortitsizma. Kanonicheskiy Wnt Signal'nyy Put' I Izmenenie Kostnogo Metabolizma Pri Glyukokortikoidnom Osteoporoze. [Phd Dissertation] Moscow. 2014]. (In Russ.).
Findling JW, Raff H. Screening and diagnosis of Cushing's syndrome. Endocrinol Metab Clin North Am. 2005;34(2):385-402, IX-X. doi: 10.1016/j.ecl.2005.02.001
Castinetti F, Morange I, Conte-Devolx B, Brue T. Cushing's sisease. Orphanet J Rare Dis. 2012;7:41. doi: 10.1186/1750-1172-7-41
Gardner D, Shoback D. Greenspan’s basic and clinical endocrinology. New York: McGraw-Hill. 2007;156-165.
Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. Williams Textbook of Endocrinology. Elsevier Health Sciences. 2015.
Praw SS, Heaney AP. Medical treatment of Cushing's disease: overview and recent findings. Int J Gen Med. 2009;2:209-217. PMC2840568
Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526-1540. doi: 10.1210/jc.2008-0125
Guaraldi F, Salvatori R. Cushing syndrome: maybe not so uncommon of an endocrine disease. J Am Board Fam Med. 2012;25(2):199-208. doi: 10.3122/jabfm.2012.02.110227
Ferone D, Pivonello C, Vitale G, et al. Molecular basis of pharmacological therapy in Cushing's disease. Endocrine. 2014;46(2):181-198. doi: 10.1007/s12020-013-0098-5
Белая Ж.Е., Рожинская Л.Я., Мельниченко Г.А., Дедов И.И. Современный взгляд на скрининг и диагностику эндогенного гиперкортицизма. // Проблемы эндокринологии. - 2012. - Т.58. - №4. - С. 35-41. [Belaia ZE, Rozhinskaia LI, Mel'nichenko GA, Dedov II. Current views of the screening and diagnostics of endogenous hypercorticism. Probl Endokrinol (Mosk). 2012;58(4):35-41]. (In Russ.). doi: 10.14341/probl201258435-41
Atkinson AB, Kennedy A, Wiggam MI, et al. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf). 2005;63(5):549-559. doi: 10.1111/j.1365-2265.2005.02380.x
Brada M, Rajan B, Traish D, et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf). 1993;38(6):571-578.
Valderrabano P, Aller J, Garcia-Valdecasas L, et al. Results of repeated transsphenoidal surgery in Cushing's disease. Long-term follow-up. Endocrinol Nutr. 2014;61(4):176-183. doi: 10.1016/j.endonu.2013.10.008
Bertagna X, Bertagna C, Laudat MH, et al. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J Clin Endocrinol Metab. 1986;63(3):639-643. doi: 10.1210/jcem-63-3-639
Castinetti F, Morange I, Jaquet P, et al. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. Eur J Endocrinol. 2008;158(1):91-99. doi: 10.1530/EJE-07-0514
Korlym (mifepristone) tablets prescribing information [Internet]. Corcept Therapeutics Inc. 2012. Available On: http://www.corcept.com/news_events/view/pr_1329524335
Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol. 2013;34(3):228-252. doi: 10.1016/j.yfrne.2013.07.005
Van Der Hoek J, Lamberts SW, Hofland LJ. Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. Eur J Endocrinol. 2007;156:Suppl 1:S45-S51. doi: 10.1530/eje.1.02350
Trementino L, Cardinaletti M, Concettoni C, et al. Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing's disease. Pituitary. 2015;18(1):60-67. doi: 10.1007/s11102-014-0557-x
Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2012;366(10):914-924. doi: 10.1056/nejmoa1105743
Trementino L, Cardinaletti M, Concettoni C, et al. Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review snd clinical practice considerations. Pituitary. 2015;18(3):359-365. doi: 10.1007/s11102-014-0582-9
Breitschaft A, Hu K, Hermosillo Resendiz K, et al. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract. 2014;103(3):458-465. doi: 10.1016/j.diabres.2013.12.011
Reznik Y, Bertherat J, Borson-Chazot F, et al. Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide. Diabetes Metab. 2013;39(1):34-41. doi: 10.1016/j.diabet.2012.10.005

Close metadata